Key facts
- It has raised $137.5M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Green Pine Capital Partners, Shenzhen Guozhong Venture Capital Management, SAIC Capital China, Lapam Capital, Shanghai Zhangjiang Science & Technology Venture Capital — 15 tracked in total.
- Status: Privately Held (backing).
Investors
15+- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Hexaell Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Hexaell Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hexaell Biotech
Developer of novel therapies designed for severe liver diseases. The company offers cell differentiation and production technology to carry out human-derived bioartificial liver clinical research and development, thereby enabling patients with liver diseases to have new and efficient treatment options.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 100
- Website
- hexaell.com/
- Ownership
- Privately Held (backing)
Hexaell Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hexaell Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hexaell Biotech in its N-PORT filings yet. We sweep new filings monthly.